Betta Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 3/6
Betta Pharmaceuticals has a total shareholder equity of CN¥5.7B and total debt of CN¥2.3B, which brings its debt-to-equity ratio to 40.6%. Its total assets and total liabilities are CN¥9.4B and CN¥3.6B respectively. Betta Pharmaceuticals's EBIT is CN¥406.6M making its interest coverage ratio 11.2. It has cash and short-term investments of CN¥816.4M.
Key information
40.6%
Debt to equity ratio
CN¥2.32b
Debt
| Interest coverage ratio | 11.2x |
| Cash | CN¥816.38m |
| Equity | CN¥5.73b |
| Total liabilities | CN¥3.63b |
| Total assets | CN¥9.36b |
Recent financial health updates
Recent updates
We Think That There Are Some Issues For Betta Pharmaceuticals (SZSE:300558) Beyond Its Promising Earnings
Nov 04
Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) P/E Is Still On The Mark Following 29% Share Price Bounce
Sep 30Results: Betta Pharmaceuticals Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates
Aug 07Unpleasant Surprises Could Be In Store For Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) Shares
Jul 30These 4 Measures Indicate That Betta Pharmaceuticals (SZSE:300558) Is Using Debt Reasonably Well
Jul 05Betta Pharmaceuticals' (SZSE:300558) Earnings Are Weaker Than They Seem
Apr 26Earnings Miss: Betta Pharmaceuticals Co., Ltd. Missed EPS By 6.1% And Analysts Are Revising Their Forecasts
Apr 23What Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) P/E Is Not Telling You
Apr 16Financial Position Analysis
Short Term Liabilities: 300558's short term assets (CN¥1.5B) do not cover its short term liabilities (CN¥1.8B).
Long Term Liabilities: 300558's short term assets (CN¥1.5B) do not cover its long term liabilities (CN¥1.9B).
Debt to Equity History and Analysis
Debt Level: 300558's net debt to equity ratio (26.3%) is considered satisfactory.
Reducing Debt: 300558's debt to equity ratio has increased from 26.5% to 40.6% over the past 5 years.
Debt Coverage: 300558's debt is well covered by operating cash flow (51%).
Interest Coverage: 300558's interest payments on its debt are well covered by EBIT (11.2x coverage).